KR101749967B1 - A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity - Google Patents
A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity Download PDFInfo
- Publication number
- KR101749967B1 KR101749967B1 KR1020150156867A KR20150156867A KR101749967B1 KR 101749967 B1 KR101749967 B1 KR 101749967B1 KR 1020150156867 A KR1020150156867 A KR 1020150156867A KR 20150156867 A KR20150156867 A KR 20150156867A KR 101749967 B1 KR101749967 B1 KR 101749967B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- soybean
- obesity
- present
- adipocytes
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 105
- 208000008589 Obesity Diseases 0.000 title claims abstract description 65
- 235000020824 obesity Nutrition 0.000 title claims abstract description 65
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 18
- 244000046052 Phaseolus vulgaris Species 0.000 title description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title description 5
- 244000068988 Glycine max Species 0.000 claims abstract description 81
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 81
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 78
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 210000001593 brown adipocyte Anatomy 0.000 claims abstract description 18
- 210000000636 white adipocyte Anatomy 0.000 claims abstract description 18
- 230000004069 differentiation Effects 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012454 non-polar solvent Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 abstract description 37
- 238000009825 accumulation Methods 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 35
- 239000003925 fat Substances 0.000 description 29
- 235000019197 fats Nutrition 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 24
- 230000036541 health Effects 0.000 description 14
- 230000035784 germination Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 229940108924 conjugated linoleic acid Drugs 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102100040420 Mitochondrial thiamine pyrophosphate carrier Human genes 0.000 description 6
- 101710112402 Mitochondrial uncoupling protein 1 Proteins 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 230000009245 menopause Effects 0.000 description 5
- -1 olive oil Chemical compound 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 3
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000783 alginic acid Chemical class 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003520 lipogenic effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940069755 soybean germ extract Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-M D-tartrate(1-) Chemical compound OC(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-M 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GNHOJBNSNUXZQA-UHFFFAOYSA-J potassium aluminium sulfate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GNHOJBNSNUXZQA-UHFFFAOYSA-J 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating obesity, which comprises a soybean germinated embryo extract, and more specifically, to a pharmaceutical composition for preventing or treating obesity comprising a soybean germinated embryo extract or a fraction thereof, To a food composition for preventing or ameliorating obesity comprising a soybean germinated embryo extract or a fraction thereof, and a feed composition.
Since the soybean germinated embryo extract of the present invention inhibits the differentiation of adipocytes and reduces the size thereof and converts white adipocytes into brown adipocytes, it suppresses accumulation of unnecessary fat in vivo, and thus is useful for preventing or treating obesity .
Description
The present invention relates to a pharmaceutical composition for preventing or treating obesity, which comprises a soybean germinated embryo extract, and more specifically, to a pharmaceutical composition for preventing or treating obesity comprising a soybean germinated embryo extract or a fraction thereof, To a food composition for preventing or ameliorating obesity comprising a soybean germinated embryo extract or a fraction thereof, and a feed composition.
Obesity or obesity is a state in which excess fat is accumulated in the body and refers to a state in which the number of adipocytes in adipose tissue is increased or the size of adipocyte is increased and fat is increased. Although obesity itself may not be a problem, the resulting social impairment and secondary complications caused by excessive fat are serious. For example, obesity causes diseases such as hypertension, hyperlipidemia, heart disease, diabetes, atherosclerosis, fatty liver, joint disorders, arthritis, sexual dysfunction, and cancer. Particularly, since the fat cells once formed are reduced in size, they are not removed naturally and remain permanently in the body, so that interest in the prevention and treatment of obesity is increasing.
Balanced diet and regular exercise are necessary to prevent or treat obesity and maintain proper weight. Recently, there have been cases where obesity is treated by taking drugs that reduce fat absorption. Such diet drugs may cause side effects such as cardiovascular diseases such as hypertension and stroke, Occasionally. In the case of severe obesity, surgical procedures such as surgery to remove fat or gastroplasty or stomach band insertion to limit the amount of food that can digest the body are performed, but the side effects of the surgery or complications resulting therefrom are reported And even deaths have been reported.
Accordingly, it is urgently required to develop a therapeutic agent for obesity which has less toxicity and side effects. Recently, alternative therapies using various active ingredients derived from natural products such as herbal medicines and foods or methods for producing various extracts have been studied. Examples thereof include a composition for prevention and treatment of obesity including extracts of herbal medicines (Korean Patent Laid-Open Publication No. 2015-0105563) or a composition for improving, preventing or treating obesity including garlic and herbal extract (Korean Patent Laid- 0085543) have been developed. However, development of a natural pharmaceutical composition or a raw material thereof, which has superior therapeutic effects and less side effects than conventional synthetic pharmaceutical compositions for obesity, has not yet been developed.
Under these circumstances, the present inventors have made intensive research to develop a therapeutic agent for obesity using a natural-derived component, and as a result, it has been found that an extract of a soybean germinated embryo produced by germinating an abandoned soybean embryo in the process of producing a processed product using soybean, Inhibiting the differentiation, reducing the size of adipocytes, and converting white adipocytes into brown adipocytes, thereby inhibiting the accumulation of unnecessary fats in vivo. Thus, the present invention has been completed.
It is an object of the present invention to provide a pharmaceutical composition for preventing or treating obesity comprising a soybean germinated embryo extract or a fraction thereof.
It is another object of the present invention to provide a method of preventing or treating obesity comprising the step of administering the composition to a subject other than a human.
It is still another object of the present invention to provide a food composition for preventing or ameliorating obesity comprising a soybean germinated embryo extract or a fraction thereof.
It is another object of the present invention to provide a feed composition for preventing or ameliorating obesity comprising a soybean germinated embryo extract or a fraction thereof.
One aspect for achieving the above object is to provide a pharmaceutical composition for preventing or treating obesity comprising a soybean germinated embryo extract or a fraction thereof.
The term "soybean germinated embryo" of the present invention means a germinated embryo obtained by germinating an embryo isolated from soybean. A method for producing a soybean germinated embryo has been known from previous studies of the present inventors (Korean Laid-Open Patent Application No. 2013-0057173). Specifically, the soybean germinated embryo may be obtained by germinating an embryo isolated from soybean, But is not limited thereto. The effect of treating the soybean germinated embryo extracts with obesity has not been known at all and has been first identified by the present inventors.
The soybean germinated embryo extract of the present invention may be obtained by extracting the soybean germinated embryo with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
The term "extract " of the present invention means an extract obtained by extracting a soybean germinated embryo, a diluted solution or concentrate of the extract, a dried product obtained by drying the extract, a preparation or a purified product of the extract, Extracts themselves and extracts of all formulations which can be formed using extracts.
In the soybean germinated embryo extract of the present invention, the method for extracting the soybean germinated embryo is not particularly limited and may be carried out according to a method commonly used in the art. Non-limiting examples of the extraction method include hydrothermal extraction, ultrasonic extraction, filtration, and reflux extraction. These may be performed alone or in combination with two or more methods.
In the present invention, the kind of the extraction solvent used for extracting the soybean germinated embryo is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water, alcohol, and a mixed solvent thereof. These solvents may be used alone or in combination. When an alcohol is used as a solvent, an alcohol having 1 to 4 carbon atoms can be specifically used.
The term "fraction " of the present invention means a product obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various components.
The fractionation method for obtaining the fraction in the present invention is not particularly limited and may be carried out according to a method commonly used in the art. As a non-limiting example of the above-mentioned fractionation method, there can be mentioned a method of treating a soybean germinated embryo extract of the present invention with a predetermined solvent to obtain a fraction from the extract.
The kind of the fraction solvent used for obtaining the fraction in the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fraction solvent include polar solvents such as water and alcohol; And non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of one or more. When an alcohol is used in the fraction solvent, an alcohol having 1 to 4 carbon atoms can be specifically used.
The soybean germination germ extract of the present invention may inhibit the differentiation of adipocytes.
The term "differentiation of adipocytes" of the present invention means that adipocyte precursor cells are converted into adipocytes, and for the purpose of the present invention, adipocytes accumulate adipocytes in the cells.
In one embodiment of the present invention, the soybean germination germ extract was found to reduce fat contained in adipocytes to a similar extent as the CLA (conjugated linoleic acid) treated group, which is also used as a weight control health functional food, It was confirmed that the effect was more excellent than the extract obtained by germinating itself (FIG. 2). This suggests that the extract can effectively be used for the treatment of obesity because it exhibits an effect of removing excess accumulated fat.
In addition, the soybean germ extract of the present invention may reduce the size of adipocytes.
The term "size of fat cells" of the present invention means the diameter of fat cells. Since the size of the cells is determined by the amount of accumulated fat in the cells, the decrease in the size of the fat cells may be a decrease in the amount of fat in the cells.
In one embodiment of the present invention, the extract was administered to an animal model of obesity induced by menopause. As a result, it was confirmed that the diameter including the short axis and the long axis length of the adipocyte decreased (FIG. 4). This suggests that the extract has an effect of reducing the amount of fat in adipocytes, and thus can be effectively used for the treatment of obesity.
In addition, the soybean germination extract of the present invention may be one which converts white adipocytes into brown adipocytes.
The term "white adipocyte " of the present invention means a fat cell that stores fat, and is a cell that causes adult diseases such as diabetes and obesity.
The term "brown adipocyte" of the present invention means a cell that burns fat as energy, and plays a role in thermoregulation and energy production.
When white adipocytes are converted to brown adipocytes, the amount of fat burned is higher than the amount of fat stored in the body, so it is easier to maintain weight even if the same amount of food is consumed.
In one embodiment of the present invention, administration of the extract to obesity-induced animal models of menopause resulted in an increase in the number of brown adipose cells and a decrease in the size of white adipocytes 5). This suggests that the extract can effectively be used for the treatment of obesity because it exhibits an effect of suppressing the accumulation of fat by saturating brown adipocytes with white adipocytes.
The term "obesity" of the present invention means excessive fat tissue in the body. A man's body fat is over 25% of body weight, a woman is over 30% of body weight is called obesity, and when the amount of calories consumed by the food is greater than the calories consumed by moving the body, obesity occurs. When obesity occurs, it appears to be fat in appearance, can easily breathe, and may be accompanied by joint pain, diabetes, and high blood pressure.
The term "prevention" of the present invention means all the actions of suppressing or delaying obesity by administration of a pharmaceutical composition containing the extract of the present invention.
The term "treatment" of the present invention means any suspicion of obesity and all symptoms that the symptoms of the onset individuals are alleviated or changed by administering the pharmaceutical composition.
The pharmaceutical composition of the present invention may contain the extract in an amount of 0.0001 to 50% by weight based on the weight of the total composition, and may include, but is not limited to, 0.01 to 10% by weight.
The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition, and the carrier may include a non-naturally occuring carrier .
The term "pharmaceutically acceptable" of the present invention means that it exhibits properties that are not toxic to the cells or humans exposed to the composition.
Specifically, the pharmaceutical composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method . In the present invention, the carrier, excipient and diluent which may be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
One aspect for achieving the above object is to provide a method for preventing or treating obesity comprising the step of administering the composition to a subject other than a human.
The term "administering" of the present invention means introducing a given substance into an individual in a suitable manner.
The term "individual" of the present invention means all animals such as rats, mice, livestock and the like, including humans who have developed or are capable of developing obesity. As a specific example, it may be a mammal including a human.
The method for preventing or treating obesity according to the present invention may specifically include the step of administering to a subject other than a human in a pharmaceutically effective amount a pharmaceutical composition for preventing or treating obesity comprising a soybean germinated embryo extract or a fraction thereof have.
The term "pharmaceutically effective amount" of the present invention means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects. The effective dose level is determined by the sex, age And other medical fields, including drugs used in combination or concurrently, with respect to body weight, health status, type of disease, severity, activity of the drug, sensitivity to the drug, method of administration, administration time, route of administration, Can be readily determined by those skilled in the art according to well known factors.
Specifically, the composition of the present invention may be administered at a dose of 0.0001 to 100 mg / kg body weight per day, more specifically 0.001 to 100 mg / kg body weight, based on the solid content. The administration may be such that the recommended dose is administered once a day or divided into several doses.
In the method for preventing or treating obesity of the present invention, the administration route and method of administering the composition are not particularly limited, and any route of administration and administration may be used as long as the composition containing the composition can reach the desired site It is possible to follow the method. Specifically, the composition may be administered orally or parenterally through various routes. Non-limiting examples of routes of administration include oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, Intramuscularly or through inhalation or the like.
One aspect of the present invention provides a food composition for preventing or ameliorating obesity comprising a soybean germinated embryo extract or a fraction thereof.
The term "improvement" of the present invention means all the actions in which the administration of the composition improves or alleviates obesity.
The term "food" of the present invention includes dairy products such as meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, various soups, drinks, tea, , A vitamin complex, a health functional food, and a health food, all of which include foods in a conventional sense.
The term "functional food" as used herein means the same term as "food for special health use" (FoSHU). In addition to nutrition, It means food. Here, the term "function" means that the structure and function of the human body have a beneficial effect for health use such as controlling nutrients or physiological action. The food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients which are conventionally added in the art. In addition, the formulations of the food can also be produced without restrictions as long as they are formulations recognized as food. The composition for food of the present invention can be manufactured in various forms, and unlike general pharmaceuticals, it has the advantage that there is no side effect that may occur when a drug is used for a long period of time, and is excellent in portability, Can be ingested as an adjuvant to promote the effect of preventing or improving obesity.
The health food refers to a food having an active health promotion or promotion effect compared with a general food, and a health supplement food refers to a food for health assistance. In some cases, the terms health functional foods, health foods, and health supplements are used.
Specifically, the health functional food is a food prepared by adding the extract of the present invention to food materials such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering, suspension or the like, But it has the advantage that there is no side effect that can occur when the food is used as a raw material and long-term use of the drug.
Since the food composition of the present invention can be routinely ingested, high efficacy against prevention or improvement of obesity can be expected, and thus it can be very usefully used.
The food composition may further comprise a physiologically acceptable carrier. The type of carrier is not particularly limited, and any carrier conventionally used in the art can be used.
In addition, the food composition may contain additional components that are commonly used in food compositions and can improve odor, taste, visual appearance, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid and the like. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) It may also include amino acids such as lysine, tryptophan, cysteine, valine, and the like.
In addition, the food composition may further contain antiseptic agents (such as potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate), bactericides (Sodium nitrite), bleach (sodium sulfite), seasoning (sodium MSG glutamate, etc.), sweeteners (dicin, cyclamate, saccharin, etc.), coloring agents , Sodium, etc.), perfume (vanillin, lactones, etc.), swelling agents (alum, potassium hydrogen D-tartrate), emulsifiers, thickeners (foams), encapsulating agents, gum bases, foam inhibitors, solvents, And may include food additives. The additives may be selected and used in appropriate amounts depending on the type of food.
The extract of the present invention can be added intact or used together with other food or food ingredients, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the food composition of the present invention may be added in an amount of not more than 50 parts by weight, specifically not more than 20 parts by weight, based on the food or beverage, when the food or drink is prepared. However, in case of long-term ingestion for health and hygiene purposes, the active ingredient may be contained in an amount not exceeding the above range and there is no problem in terms of safety.
As an example of the food composition of the present invention, it can be used as a health beverage composition. In this case, various flavors or natural carbohydrates can be added as an additional ingredient like ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; Xylitol, sorbitol, erythritol, and the like. Sweeteners include natural sweeteners such as tau Martin and stevia extract; Synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 mL of the health beverage composition of the present invention.
In addition to the above, the health beverage composition may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acid, protective colloid thickener, pH adjuster, stabilizer, Alcohols or carbonating agents, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.
The food composition of the present invention may be contained in various weight percentages as long as it can exhibit the effect of preventing or improving obesity. Specifically, the extract of the present invention may be contained in an amount of 0.00001 to 100% by weight or 0.01 to 80% by weight, But are not limited thereto.
One aspect of the present invention provides a feed composition for preventing or ameliorating obesity comprising a soybean germinated embryo extract or a fraction thereof.
The term "feed " of the present invention means any natural or artificial diet, single meal, or the like ingredients for feeding, ingesting, digesting, or suitable for the animal.
The feed may comprise a feed additive or supplementary feed.
The kind of the feed is not particularly limited, and feeds conventionally used in the art can be used. Non-limiting examples of such feeds include vegetable feeds such as cereals, muscle roots, food processing busines logistics, algae, fibers, pharmaceutical buses, oils, fats, pastes or grain by-products; Animal feeds such as proteins, inorganic substances, fats, oils, fats, oils, monocellular proteins, animal plankton or foods. These may be used alone or in combination of two or more.
Since the soybean germinated embryo extract of the present invention inhibits the differentiation of adipocytes and reduces the size thereof and converts white adipocytes into brown adipocytes, it suppresses accumulation of unnecessary fat in vivo, and thus is useful for preventing or treating obesity .
1 is a graph showing the toxicity of soybean germinated embryo extract against lipogenic precursor cell line 3T3-L1. Soybean germinated embryo extracts were treated at concentrations of 50, 100, 200, 300, 400 and 500 ㎍ / mL.
Fig. 2 is a graph showing the effect of soybean germinated embryo extract on adipocyte differentiation. After induction of adipocyte differentiation, soybean germinated embryo extracts were prepared at the concentrations of 50, 100, 200, 300, 400 and 500 / / mL and treated with the cells. As a positive control, 100 μM of CLA (conjugated linoleic acid ). Control refers to non-differentiated control adipocytes, and control + insulin refers to differentiated control adipocytes. Soybean germ extract was prepared at a concentration of 500 μg / mL and treated with the cells.
FIG. 3 shows the effect of soybean germinated embryo extract (SA) and soybean germination extract (SG) on gene expression associated with adipocyte differentiation, wherein A is a Western blot image showing the amount of gene expression, B is the expression amount The results are shown in FIG. PPARγ, SREBP-1c and CEBPα were genes promoting the differentiation of adipocytes and Actin gene was used as a control group for comparing the expression levels of the genes.
FIG. 4 shows the effect of soybean germinated embryo extract on adipocyte size, A is an image showing the size of fat cells, and B is a graph showing the results of measuring the size. Obesity-induced mouse (OVX) was used as a negative control group by surgically removing ovaries. The mice were administered with 0.1 mg / kg, 1 mg / kg and 5 mg / kg of soybean germinated embryo extract, Respectively.
FIG. 5 shows the effect of soybean germinated embryo extract on white adipocytes and brown adipocytes. FIG. 5A shows the size of white adipocytes and FIG. 5B shows the number of brown adipocytes relative to the number of white adipocytes This is a graph showing the results. Obesity-induced mouse (OVX) was used as a negative control group by surgically removing ovaries. The mice were administered with 0.1 mg / kg, 1 mg / kg and 5 mg / kg of soybean germinated embryo extract, Respectively.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Example 1. Beans Germination embryo Evaluation of cytotoxicity of extracts
In order to prepare the soybean germinated embryo extract, the soybean germinated embryo prepared according to the previous study of the present inventor was used. Specifically, the soybean embryo was immersed in running water and germinated. After about 24 hours, the soybean germinated embryo was harvested, lyophilized and powdered to obtain a soybean germinated embryo powder. The resulting soybean germinated embryo powder was extracted by adding a fermented syrup, followed by filtration to obtain a liquid component, and the liquid component was lyophilized to obtain a soybean germana extract.
Then, in order to confirm the safety of the soybean germinated embryo extract, cytotoxicity of the extract to the cells was evaluated. Specifically, the lipogenic precursor cell line 3T3-L1 was subcultured in a 96-well plate at a density of 2 × 10 2 cells / well, and seed extracts of 50, 100, 200, 300, 400 and 500 μg / And cultured for 24 hours or 72 hours. After the completion of the incubation, the water-insoluble formazan formed by the addition of the MTT solution was dissolved in a dimethyl sulfoxide solution, and the optical density (OD value) of the dissolved formazan at 595 nm was measured. The relative cell viability (%) was assessed by measurement.
As a result, as shown in Fig. 1, it was confirmed that the soybean germinated embryo extract did not show cytotoxicity at all concentrations. As a result, the soybean germinated embryo extract of the present invention was found to be a safe substance free from harm to human body.
Example 2. Soybean for fat cell differentiation Germination embryo Analysis of the effect of extracts
Example 2-1. bean Germination embryo Analysis of lipid-lowering activity of extracts
To examine the effect of the extract on obesity treatment, the effect of soybean germinated embryo extract on the degree of adipocyte differentiation was analyzed.
3T3-L1 cells (Korean Cell Line Bank, Korea) were purchased from a fetal bovine serum (FBS) and 1% antibiotics (100 U / ml penicillin and 0.1 mg / mL streptomycin) ) In DMEM (Dulbecco's modified eagle medium) medium at 37 ° C under 5% CO 2 (95% air).
The cultured 3T3-L1 cells were treated with soybean germinated embryo extracts at a concentration of 50, 100, 200, 300, 400 and 500 / / mL, and the differentiation inducers (FBS, IBMX, dexanmethasone and Insulin) for 72 hours to differentiate into adipocytes. At this time, adipocyte without any substance was used as a control group and adipocyte treated with the same concentration of CLA (conjugated linoleic acid) was used as a comparative group.
As a result, as shown in FIG. 2, differentially treated control adipocytes (control + insulin) treated with insulin compared to control non-differentiated control fat cells (control) showed an increase in accumulated fat in the cells. In addition, it was confirmed that the soybean germinated embryo extract reduced the fat content of the differentiated adipocytes to the extent similar to that of CLA (conjugated linoleic acid) Was found to be better as the concentration of the extract increased. In addition, the soybean germinated embryo extract of the present invention was superior to the extract obtained by germinating the soybean itself, in that the fat cell differentiation inhibition effect was superior and the fat accumulation inhibition effect was also superior.
Example 2-2. Soy bean for fat cell differentiation Germination embryo Analysis of the effect of extracts
In order to analyze the effect of soybean germinated embryo extract on differentiation of adipocytes, the effect of the extract on the expression of biomarkers associated with adipocyte differentiation was examined.
Specifically, the degree of protein expression of PPARγ, SREBP-1c and CEBPα, genes promoting differentiation of adipocytes, was confirmed by Western blotting.
As a result, as shown in FIG. 3, the expression of PPARγ, SREBP-1c and CEBPα was decreased in the experimental group treated with the extract, as compared with control cells treated with DMSO. These results indicate that the soybean germinated embryo extract can inhibit fat cells from accumulating fat by inhibiting differentiation of adipocytes. In addition, when the soybean germinated embryo extract of the present invention was compared with the extract (SG) obtained by germination of the soybean itself, it was confirmed that the gene expression suppressing effect was superior and the fat accumulation inhibiting effect was also superior .
Example 3. Beans for fat cells in vivo Germination embryo Analysis of the effect of extracts
Example 3-1. Soybeans for fat cell size Germination embryo Analysis of the effect of extracts
In order to evaluate the effect of the extract on obesity, the effect of soybean germinated embryo extract on the fat cell size of obesity - induced animal models was analyzed by surgically removing ovaries. After menopause, as the amount of hormone secretion decreases, the basal metabolic rate decreases, and as fat decomposition decreases, the likelihood of obesity increases.
Specifically, the ovaries were removed from the ovaries by using 8-week-old female C57BL / 6 mice. For ovariectomy, a 1-2 cm skin incision was made in the lower middle region of the abdomen and forceps were applied to the ovaries (ovary) and oviduct (oviduct). One week after ovariectomy, randomized grouping was divided into randomized groupings using body weight measurement. Sonde was orally administered with 0.1, 1 and 5 mg / kg of soybean germinated embryo extracts six times a week.
After the end of the administration, the adipose tissue surrounding adipose tissue was removed, fixed with 10% formalin, embedded in paraffin, and the adipose tissue was sectioned to 4 μm. Then, the specimens were stained with HE (Hematoxylin and Eosin) staining. Observation of adipocytes was performed at a magnification of 400 × under a microscope. The lengths of long and short axes were measured for 10 cells in one field of view. The mean value of the long axis and short axis observed at 3 fields per individual was calculated and the average value of the groups was calculated.
As a result, as shown in FIG. 4, it was confirmed that the short axis and the long axis length of the adipocyte were increased in the negative control group (OVX) caused by menopause due to obesity as compared with the normal control group (con). On the other hand, it was confirmed that the diameter of the adipocyte was decreased in the test group administered with the extract, and the higher the concentration of the extract was, the higher the concentration of the extract (5 mg / kg / day) In the experimental group, the size of adipocytes was decreased to a level similar to that of the normal control group.
Example 3-2. Beans for white adipocytes and brown fat cells Germination embryo Analysis of the effect of extracts
Since white adipocytes are responsible for the development of adult diseases such as diabetes or obesity, brown adipocytes play a role in preventing obesity by burning fat as energy. Therefore, in order to evaluate the therapeutic effect of the extract on obesity, The effect of ovariectomy on white adipocytes or brown adipose cells in obesity - induced animal models was analyzed.
Specifically, the soybean germinated embryo extract was administered to an obesity-inducing animal model according to the method of Example 3-1, and the number of white adipocytes and brown adipocytes of the animal were examined. Immunohistochemistry using fatty acid oxidation-related UCP1 (mitochondrial uncoupling protein 1) protein was performed on adipose tissue cells, and brown adipocytes (UCP1) showing positive UCP1 response at three fields per subject at a microscope magnification of 200 times Were measured using LAS image analysis software.
As a result, as shown in FIG. 5, it was confirmed that the negative control group (OVX) and the normal control group (con) caused by obesity caused by menopause had fewer cells showing UCP1 positive reaction around and inside gonadal fat . On the other hand, in the test group administered with the extract, the number of UCP1-positive cells was increased compared to the negative and normal control groups, and at the same time, the size of white adipocytes decreased. This effect was better as the concentration of the extract was higher, and the number of brown adipocytes increased about 3.2 times in the experimental group administered with the high concentration of the extract (5 mg / kg / day) Respectively.
From the above results, it was found that the soybean germinated embryo extract showed a decrease in the size of white adipocytes and saturating the cells with brown adipocytes, thereby suppressing accumulation of adipocytes.
From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.
Claims (11)
Wherein the soybean germinated embryo is obtained by germinating an embryo isolated from soybean.
Wherein the soybean germinated embryo is obtained by germinating an embryo isolated from soybean.
Wherein the soybean germinated embryo is obtained by germinating an embryo isolated from soybean.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150156867A KR101749967B1 (en) | 2015-11-09 | 2015-11-09 | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity |
| PCT/KR2016/002069 WO2017082479A1 (en) | 2015-11-09 | 2016-03-02 | Pharmaceutical composition for prevention or treatment of obesity comprising bean germinated embryo extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150156867A KR101749967B1 (en) | 2015-11-09 | 2015-11-09 | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170054116A KR20170054116A (en) | 2017-05-17 |
| KR101749967B1 true KR101749967B1 (en) | 2017-06-23 |
Family
ID=58695668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150156867A KR101749967B1 (en) | 2015-11-09 | 2015-11-09 | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101749967B1 (en) |
| WO (1) | WO2017082479A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190104819A (en) | 2018-03-02 | 2019-09-11 | (주)셀턴 | Process for preparing organic acid glycerin esters containing isoflavone / soyasaponin complex extracted from soybean and cosmetic composition containing the same |
| KR20200051156A (en) | 2018-11-05 | 2020-05-13 | (주)화인에프티 | Manufacturing Method of Sunsik Comprsing Extract from Germinated Gemmule of Bean |
| KR20200061836A (en) | 2018-11-26 | 2020-06-03 | (주)비티엔 | Composition for improving anti-wrinkling containing nucleic acid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005145826A (en) * | 2003-11-11 | 2005-06-09 | Kazuhiro Kotani | Composition containing sprouted bean for prevention and/or treatment of lifestyle disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100706279B1 (en) * | 2005-11-11 | 2007-04-12 | (주)아모레퍼시픽 | Medicine and food compositions for improvement of obesity |
| KR101640258B1 (en) * | 2010-07-05 | 2016-07-15 | 주식회사 엘지생활건강 | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and L-carnitine |
| KR102200014B1 (en) * | 2013-05-06 | 2021-01-08 | (주)아모레퍼시픽 | Composition for preventing and treating climacteric symptoms comprising extract of bean containing coumestrol |
| KR20140141871A (en) * | 2013-05-31 | 2014-12-11 | 고려대학교 산학협력단 | Composition comprising germinated soybean peptides for anti-obesity |
-
2015
- 2015-11-09 KR KR1020150156867A patent/KR101749967B1/en active IP Right Grant
-
2016
- 2016-03-02 WO PCT/KR2016/002069 patent/WO2017082479A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005145826A (en) * | 2003-11-11 | 2005-06-09 | Kazuhiro Kotani | Composition containing sprouted bean for prevention and/or treatment of lifestyle disease |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190104819A (en) | 2018-03-02 | 2019-09-11 | (주)셀턴 | Process for preparing organic acid glycerin esters containing isoflavone / soyasaponin complex extracted from soybean and cosmetic composition containing the same |
| KR20200051156A (en) | 2018-11-05 | 2020-05-13 | (주)화인에프티 | Manufacturing Method of Sunsik Comprsing Extract from Germinated Gemmule of Bean |
| KR20200061836A (en) | 2018-11-26 | 2020-06-03 | (주)비티엔 | Composition for improving anti-wrinkling containing nucleic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017082479A1 (en) | 2017-05-18 |
| KR20170054116A (en) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101982326B1 (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
| KR101640258B1 (en) | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and L-carnitine | |
| KR20130102295A (en) | Composition comprising extract of humulus japonicus or humulus scandens for preventing or treating of metabolic diseases | |
| KR101749967B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
| KR102189891B1 (en) | Composition for preventing or treating andropause related symptoms comprising the extract of rice bran | |
| KR102081984B1 (en) | A pharmaceutical composition comprising extract from wheat sprowt for preventing or treating osteoporosis | |
| KR101917363B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating menopausal disorder | |
| KR102043404B1 (en) | A pharmaceutical composition comrprising Morus alba Linne extract for preventing or treating benign prostatic hyperplasia | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR20210130588A (en) | Composition for anti-obesity comprising extract of Sargassum horneri | |
| KR20170054115A (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating osteoporosis | |
| KR102487651B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of wheat sprout | |
| KR102275268B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR101898261B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating osteoporosis | |
| KR101018404B1 (en) | Compositions for reducing cholesterol comprising extracts of Vaccinium oldhami Miquel leaf as an active ingredient | |
| KR20160094313A (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
| KR102380295B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of oat | |
| KR20200072952A (en) | A composition for prevention and treatment of osteoporosis comprising extracts of Saechalssalbori | |
| KR102595767B1 (en) | Composition for preventing, improving, or treating cachexia containing extract of Buddlejae Flos | |
| KR100533283B1 (en) | Composition comprising extract of herbal mixture for prevention or treatment of osteoporosis | |
| KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR20100041050A (en) | Compositions for the prevention and treatment of obesity comprising extracts of vaccinium oldhami miquel leaf as an active ingredient | |
| KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract | |
| KR101959735B1 (en) | A composition for enhancing anti-cancer effect of cisplatin in colorectal cancer comprising safflower seed extract | |
| KR20170130082A (en) | A Composition Comprising the root extract of Achyranthes japonica NAKAI for preventing or improving the hormonal abnormal syndrome in women |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |